TrialThe Lancet. Respiratory medicine2025

Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.

Hervé Léna et al.PubMed ↗Publisher ↗

No numbers read from the abstract.